Shares of Wockhardt experienced a significant decline of 9 percent in early trading on Tuesday, making it one of the top losers in the Nifty Smallcap 100 index. The drop followed a period of profit-taking by investors, triggered by a recent surge in the stock price due to regulatory approvals for its novel antibiotic, Zaynich, in both the United States and India.
The stock closed at ₹1,966.20, reflecting an 8.67 percent decrease after reaching a low of ₹1,940.00. This decline follows a remarkable rise of 36.77 percent over the past three trading sessions. Wockhardt shares had reached a 52-week high of ₹2,422.30 on June 1, 2026, compared to a closing price of ₹1,771 on May 27, 2026.
The recent price rally can be attributed to the approval by the US Food and Drug Administration (USFDA) for Zaynich (cefepime and zidebactam), which is designed as an intravenous antibiotic treatment for adults with complicated urinary tract infections (cUTI).
Wockhardt plans to market Zaynich independently in international markets and India, a strategic decision noted by Founder and Chairman Habil Khorakiwala, who remarked that this approach deviates from the industry norm of forming partnerships for global distribution. Khorakiwala highlighted the approval as a landmark achievement for a new chemical entity developed in India.
Additionally, on May 28, 2029, Wockhardt informed stock exchanges that the Central Drugs Standard Control Organisation (CDSCO) had granted authorization for the import and marketing of Zaynich in India.
This recent development underscores Wockhardt’s forward momentum in the pharmaceutical sector, though the stock market’s reaction indicates volatility as investors adjust their positions.
Published on June 2, 2026.
